ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,187.67
      0.00%
      US Tech 100
      17,585.20
      -0.16%
      Dow Jones
      39,056.39
      0.44%
      Brent Oil
      83.56
      0.84%
      Bitcoin
      61,031.14
      -2.09%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Monte Rosa Therapeutics Inc (GLUE)

      7. Monte Rosa Therapeutics Inc (GLUE) News

      GLUE

      Monte Rosa Therapeutics (GLUE)

      Monte Rosa Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:GLUE
      DateTimeSourceHeadlineSymbolCompany
      1:05PMiHub NewswireFeaturedElement79 Gold Corp Successfully Closes Maverick Springs Option Agreement
      05/02/20244:01PMGlobeNewswire Inc.Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerNASDAQ:GLUEMonte Rosa Therapeutics Inc
      03/14/20247:00AMGlobeNewswire Inc.Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
      03/11/20247:00AMGlobeNewswire Inc.Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorNASDAQ:GLUEMonte Rosa Therapeutics Inc
      01/31/20247:00AMGlobeNewswire Inc.Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      01/08/20247:47AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
      01/08/20247:15AMGlobeNewswire Inc.Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024NASDAQ:GLUEMonte Rosa Therapeutics Inc
      01/04/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      01/04/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      01/04/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      01/04/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      01/04/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      01/03/20247:00AMGlobeNewswire Inc.Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
      11/21/20237:00AMGlobeNewswire Inc.Monte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
      11/09/20237:27AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
      11/09/20237:00AMGlobeNewswire Inc.Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
      11/07/202310:00AMGlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      10/27/20237:00AMGlobeNewswire Inc.Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      10/26/20235:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
      10/26/20234:55PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
      10/26/20234:30PMGlobeNewswire Inc.Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq RulesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      10/17/20237:55AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
      10/17/20237:00AMGlobeNewswire Inc.Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid TumorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
      10/17/20237:00AMGlobeNewswire Inc.Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      08/18/20234:00PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      08/15/20235:16PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
      08/10/20237:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
      08/10/20237:19AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
      08/10/20237:15AMGlobeNewswire Inc.Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
      07/26/20237:53AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:GLUE